TSTunlanut Sapankaew

Tunlanut Sapankaew

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tunlanut Sapankaew has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Ammarin Thakkinstian

    Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

    2 shared publications
  • Gareth J. McKay

    Centre for Public Health, Queen’s University Belfast, Belfast, Northern Ireland, United Kingdom

    2 shared publications
  • John Attia

    School of Medicine and Public Health, University of Newcastle, Callaghan, New South Wales, Australia

    2 shared publications
  • Atiporn Ingsathit

    Department of Clinical Epidemiology and Biostatistics Faculty of Medicine Ramathibodi Hospital Mahidol University Bangkok Thailand

    1 shared publication
  • Chaiyawat Suppasilp

    Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

    1 shared publication
  • Kamolpat Chaiyakittisopon

    Department of Clinical Epidemiology and Biostatistics Faculty of Medicine Ramathibodi Hospital Mahidol University Bangkok Thailand

    1 shared publication

Latest Publications

  • Open Access

    Machine Learning Prediction of Stroke Occurrence: A Systematic Review

    by Sermkiat Lolak, Chaiyawat Suppasilp, Napaphat Poprom, Tunlanut Sapankaew, Myat Su Yin, Ratchainant Thammasudjarit, Gareth J. McKay, John Attia, Ammarin Thakkinstian

    Background Machine learning is nowadays commonly used for disease prediction, including cardiovascular disease. There is growing evidence of the effectiveness of machine learning algorithms for stroke risk prediction models. Aims A systematic review was conducted to identify and comprehensively evaluate the available evidence. Summary of review Relevant studies were identified from the three electronic databases (i) MEDLINE via Pubmed, (ii) Scopus, and (iii) IEEE Xplore from inception to 1st December 2020. Out of 12,626 studies identified, 40 used machine learning for ischemic or hemorrhagic stroke risk prediction models. Synthesis without meta-analysis identified that a boosting algorithm (median C-statistics = 0.9 (interquartile range [IQR]: 0.88-0.92)), and neural network (median C-statistic = 0.80 (IQR: 0.77-0.92)) performed best among ML models in the low risk of bias studies. Moreover, a boosting algorithm also performed best in overall (both low and high risk of bias) studies (median C-statistic = 0.92 (IQR: 0.90-0.95)). Conclusions The systematic review found promising results of the ML algorithm model performances compare with the gold standard conventional models, such as FSRP (C-statistic 0.653) and revised FSRP (C-statistic 0.716). In term of the algorithm, boosting and neural networks are robust, but are considered as black-box models, since they are composed of non-linearity and complex algorithms. It remains questionable whether a physician would adapt these algorithms to use in a real clinical setting. Moreover, less than half of the studies (16 out of 40) were at low risk of bias in our systematic review. More researches with good methodology and study design, alongside explainable and good performance models, may become available in the future. Trial Registration Information The International Prospective Register of Systematic Reviews (PROSPERO) database (ID: CRD42021234081).

  • Open Access

    Efficacy and safety of conventional antiviral agents in preventive strategies for cytomegalovirus infection after kidney transplantation: a systematic review and network meta‐analysis

    by Narisa Ruenroengbun, Pawin Numthavaj, Tunlanut Sapankaew, Kamolpat Chaiyakittisopon, Atiporn Ingsathit, Gareth J. Mckay, John Attia, Ammarin Thakkinstian

    Cytomegalovirus (CMV) infection is common in kidney transplantation (KT). Antiviral-agents are used as universal prophylaxis. Our purpose aimed to compare and rank efficacy and safety. MEDLINE, Embase, SCOPUS, and CENTRAL were used from inception to September 2020 regardless language restriction. We included randomized clinical trials (RCTs) comparing the CMV infection/disease prophylaxis among antiviral-agents in adult KT recipients. Of 24 eligible RCTs, prophylactic valganciclovir (VGC) could significantly lower the overall CMV infection and disease risks than placebo with pooled risk differences (RDs) [95% confidence interval (CI)] of −0.36 (−0.54, −0.18) and −0.28 (−0.48, −0.08), respectively. Valacyclovir (VAC) and ganciclovir (GC) significantly decreased risks with the corresponding RDs of −0.25 (−0.32, −0.19) and −0.30 (−0.37, −0.22) for CMV infection and −0.26 (−0.40, −0.12) and −0.22 (−0.31, −0.12) for CMV disease. For subgroup analysis by seropositive-donor and seronegative-recipient (D+/R−), VGC and GC significantly lowered the risk of CMV infection/disease with RDs of −0.42 (−0.84, −0.01) and −0.35 (−0.60, −0.12). For pre-emptive strategies, GC lowered the incidence of CMV disease significantly with pooled RDs of −0.33 (−0.47, −0.19). VGC may be the best in prophylaxis of CMV infection/disease follow by GC. VAC might be an alternative where VGC and GC are not available.